Navigation Links
deCODE discovers genetic markers that improve the power of PSA testing for detecting prostate cancer
Date:12/15/2010

Reykjavik, ICELAND, 15 December 2010 Scientists from deCODE genetics and academic colleagues from Iceland, the UK, US, Netherlands, Spain and Romania today report the discovery of a set of single-letter variations in the sequence of the human genome (SNPs) that impact individual baseline levels of prostate specific antigen, or PSA. Testing for PSA levels is the most commonly used screening tool for the detection of prostate cancer. A prostate biopsy is routinely recommended for men with PSA above a certain threshold. However, PSA levels can rise for reasons unrelated to prostate cancer and baseline healthy levels vary substantially between individuals, resulting in many men without cancer being biopsied while cancer in others is not detected. The paper published today demonstrates that analysis of four SNPs can be used to derive a personalized PSA threshold that more accurately identifies those men who are more likely to have a positive biopsy and for whom one should therefore be recommended.

"This is straighforward genetics with direct clinical utility. Detected early, prostate cancer can be treated with near total success. The challenge is to more effectively risk stratify the population, identifying and biopsying those at high risk and with aggressive disease while minimizing the number of negative biopsies we perform. And using the genetics we are improving the sensitivity and specificity of PSA testing. Like virtually every protein in the body, PSA levels vary between individuals according to SNPs that regulate gene expression. The SNPs reported today enable us to personalize PSA thresholds, thereby changing the recommendation on whether to biopsy for a substantial proportion of men. Moreover, the discriminatory power of testing for these SNPs is highest when done in tandem with the SNPs associated directly with risk of the disease measured by our deCODE ProstateCancer test. We are working to swiftly incorporate these PSA markers into our testing portfolio," said Kari Stefansson, CEO of deCODE and senior author on the study.

The paper, entitled "Genetic correction of PSA values using sequence variants associated with PSA levels," is published today online in Science Translational Medicine at www.ScienceTranslationalMedicine.org and will appear in an upcoming print edition of the journal. The study was conducted in several stages and involved tens of thousands of men with and without prostate cancer. First, more than 300,000 SNPs were analyzed in 16,000 Icelandic men with PSA measurements but who had never been diagnosed with prostate cancer. SNPs that correlated with PSA levels were identified and then validated in a cohort from the UK. These SNPs were then studied in large case-control cohorts from Iceland, the Netherlands, Spain, Romania and the US to establish the association with PSA levels independent of risk of prostate cancer itself. The authors then demonstrated how measuring four SNPs correlated with PSA levels can be used to obtain a personalized threshold for when to biopsy, and that using such thresholds improves the ratio of positive to negative biopsies. The greatest improvement in prediction accuracy was seen when men are tested both for the PSA correction SNPs as well as a panel of prostate cancer risk SNPs detected by the deCODE ProstateCancer test.


'/>"/>

Contact: Edward Farmer
edward.farmer@decode.is
354-863-1923
deCODE genetics
Source:Eurekalert

Related medicine news :

1. Scientists decode secrets of a very common virus that can cause cancer
2. Physicists use graphene to decode DNA
3. The language of RNA decoded: Study reveals new function for pseudogenes and noncoding RNAs
4. UT professor defines play, discovers even turtles need recess
5. Research discovers how the deaf have super vision
6. Colorado researcher discovers mechanism for changing adult cells into stem-like cells
7. Researcher at Childrens Hospital LA discovers way to overcome radiation resistance in leukemia
8. TGen-Mayo Clinic study discovers role of DNA methylation in multiple myeloma blood cancer
9. Virginia Tech professor discovers new TB pathogen
10. UCSF-led team discovers familial link in rare childhood leukemia
11. UR discovers new way to boost vaccines, seeks patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... 10 Best Water is excited ... bottled water brand owners that topped the list as a result of their commitment ... The premier brand was Tibet 5100, a top notch water company that specializes in ...
(Date:2/10/2016)... ... 10, 2016 , ... Intalere’s 2016 Executive Forum, taking place ... the country’s top healthcare executives to share insights on transformational strategies to drive ... is the provider-centric perspective, experience, expertise and strategy shared by the participants,” said ...
(Date:2/10/2016)... ... February 10, 2016 , ... Armune BioScience signed ... their network of laboratory service centers across the country. Launched in April of 2015, ... the detection of prostate cancer. Apifiny order volume exceeded 3,000 tests in 2015. Primary ...
(Date:2/10/2016)... ... 10, 2016 , ... A national ergonomics pioneer , ... event March 9-11, 2016. Hosted by Ohio's Bureau of Worker's Compensation, the expo ... longest running and largest worker's compensation event in Ohio, organizers of the safety ...
(Date:2/10/2016)... Jacksonville, Florida (PRWEB) , ... ... ... of North Florida – 1 UNF Drive, Jacksonville, FL 32224, February 26th: ... $30, February 27th: Elite Division - Time: 7:00pm – 10:00pm | Ticket ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... WINDSOR, ON , Feb. 10, 2016 /PRNewswire/ ... Perry , has announced the release of an ... This is a revolutionary breakthrough in the treatment ... environmental radiation exposure. It will assist in the ... are present. It will also protect only the ...
(Date:2/10/2016)... 10, 2016  Silicon Biosystems Menarini Inc., a ... help uncover the biological complexities of disease at ... developer of innovative technologies for genomics research, today ... at enabling translational researchers to obtain high-quality sequencing ... tumor and normal cells in an optimized and ...
(Date:2/10/2016)... -- Until recently, the options for reducing the appearance of ... approved the non-invasive Coolsculpting treatment, which removes fat cells ... in 2010 for the abdomen and this approval was ... this add-on approval, the experts at Laser Therapy Health ... CoolMini, to address smaller areas of fat. ...
Breaking Medicine Technology: